News | April 15, 2026
FDA presses 2,200+ companies to fix missing clinical trial results
Move amid evidence of widespread reporting gaps
Move amid evidence of widespread reporting gaps
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Subscribe To Our Newsletter & Stay Updated
